TrialBlood2014
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
Sarah E M Herman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
163 papers cite itlatest 60 shown
this paperpooled ittrialcites it